Clinical trials: Albumins
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Endothelial Dysfunction
Endothelial Function After Cardiac Surgery
The purpose of this study is to evaluate whether patients receiving human albumin for plasma volume replacement during cardiac surgery have improved postoperative endothelial function compared to patients receiving 6%…
- Trial name
- NCT02882074
- Testing
- Human albumin, Hydroxyethyl starch
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- The Cleveland Clinic
Focus of the Study:Protein Binding Characteristics of Voriconazole.
Plasma Protein Binding Characteristics of Voriconazole
The purpose of this study is to investigate the influence of hypoalbuminemia on the protein binding characteristics of the antifungal drug voriconazole in ICU patients.
- Trial name
- NCT01812473
- Testing
- Blood sampling
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00856492
- Testing
- bevacizumab, pegfilgrastim, cyclophosphamide
- Where
- 366 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of Pancreas
Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy
A pilot randomized feasibility trial with a blinded evaluator.
- Trial name
- NCT05374876
- Testing
- Hand Therapy Until CIPN, Traditional Occupational Therapy (TOT)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- HonorHealth Research Institute
Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
- Trial name
- NCT02009332
- Testing
- ABI-009, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aadi Bioscience, Inc.
Subarachnoid Hemorrhage
Treatment of Subarachnoid Hemorrhage With Human Albumin
The purpose of this study is to evaluate the tolerability and safety of 25 percent human albumin therapy in patients with subarachnoid hemorrhage.
- Trial name
- NCT00283400
- Testing
- 25% human albumin
- Where
- 6 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a…
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Trial name
- PIPAC-nabpac (NCT03304210)
- Testing
- PIPAC with Abraxane
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body…
- Conditions
- Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
- Trial name
- NCT01463072
- Testing
- Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Type 1 Diabetes
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who…
- Trial name
- PREVENTKD (NCT00729365)
- Testing
- Ramipril
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Northwestern University
Inflammatory Breast Cancer, Stage IIA Breast Cancer
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
This phase II trial studies how well carboplatin and nab-paclitaxel before surgery work in treating patients with triple negative breast cancer that is inflammatory or has spread from where it started to nearby tissue or lymph…
- Conditions
- Inflammatory Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01525966
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study.
- Trial name
- NCT00629499
- Testing
- nab paclitaxel, Cyclophosphamide, Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- SCRI Development Innovations, LLC
Hemophilia B
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
This study will examine the pharmacokinetics, safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children who have previously received factor replacement therapy for hemophilia B.
- Trial name
- NCT01662531
- Testing
- rIX-FP
- Where
- 17 sites in Australia, Austria and 8 more
- Volunteers
- 27 people
- Sponsor
- CSL Behring
Sepsis
Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital
The aim of this research study is to compare two different fluids (Human Albumin Solution (HAS) and Balanced Crystalloid that are given via a drip to patients with severe infection (sepsis).
- Trial name
- ABC Sepsis (NCT04540094)
- Testing
- Human albumin, Balanced crystalloid solution
- Where
- 15 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Edinburgh
Breast Cancer
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00675259
- Testing
- bevacizumab, carboplatin, nab-paclitaxel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hemophilia A
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
The purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are younger than 6 years of age, with severe or moderately…
- Trial name
- NCT00543439
- Testing
- Moroctocog alfa (AF-CC)
- Where
- 28 sites in United States, Argentina and 11 more
- Volunteers
- 66 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes
HbA1c is widely used as the gold standard for evaluating glycemic control. However, in patients who need adjusting hypoglycemic regimen, A1c was not a sensitive marker.
- Trial name
- NCT05227677
- Testing
- GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
This partially randomized phase I/II trial studies the side effects and best dose of WEE1 inhibitor AZD1775 when given together with paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride and how…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma
- Trial name
- NCT02194829
- Testing
- AZD1775, Gemcitabine, Nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
This is a randomized, placebo-controlled, double-blind, phase II trial of nab-paclitaxel with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer.
- Trial name
- NCT02788981
- Testing
- Mifepristone, Nab-Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Chicago
Breast Cancer
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin.
- Trial name
- NCT00093145
- Testing
- Albumin-bound paclitaxel, Carboplatin, Herceptin®
- Where
- 14 sites in United States
- Volunteers
- 32 people
- Sponsor
- Celgene